Zevra Therapeutics
ZVRA
77 hedge funds and large institutions have $52.1M invested in Zevra Therapeutics in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
25% more capital invested
Capital invested by funds: $41.6M → $52.1M (+$10.5M)
8% more funds holding
Funds holding: 71 → 77 (+6)
7.76% more ownership
Funds ownership: 24.07% → 31.82% (+7.8%)
37% less call options, than puts
Call options by funds: $979K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$11.5M |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$757K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$695K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$312K |
| 5 |
State Street
Boston,
Massachusetts
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$263K |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
-$250K |
| 3 |
Morgan Stanley
New York
|
-$118K |
| 4 |
VF
Virtu Financial
New York
|
-$112K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$63.4K |
ZVRA Hedge Fund Activity: Q3 2023 in Review
77 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2023, worth a combined $52.1M — up 25% from $41.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ZVRA positions and 6 closed out — a net gain of 6 holders — while 25 added to existing stakes and 16 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $11.5M. The largest seller was BlackRock, cutting an estimated $263K.
- 77 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2023, up from 71 in Q2 2023.
- Funds reported $52.1M of Zevra Therapeutics stock for Q3 2023, up 25% quarter-over-quarter.
- 12 funds opened new Zevra Therapeutics positions in Q3 2023 and 6 closed out, a net change of +6 holders.
- The largest Zevra Therapeutics buyer in Q3 2023 was Nantahala Capital Management, an estimated $11.5M added.
- The largest Zevra Therapeutics seller in Q3 2023 was BlackRock, an estimated $263K sold.
Based on aggregated 13F filings for Q3 2023.